# US 11,298,263 B2 · Method of mitigating myopia development and related instrumentation > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,298,263 B2 - Document ID: US11298263B2 - Status: Granted - Kind: B2 - Application number: 16/513,132 - Filed: 2019-07-16 - Published: 2021-01-21 - Granted: 2022-04-12 - Earliest claimed: 2019-07-16 - Applicants: Jack T. Holladay - Inventors: Jack T. Holladay - Web page: https://patentgrep.com/patent/US11298263B2 ## CPC - A61B 3/028: for testing visual acuity; for determination of refraction, e.g. phoropters - A61F 9/00736: {Instruments for removal of intra-ocular material or intra-ocular injection, e.g. cataract instruments (A61F9/008 takes precedence)} - A61B 3/103: for determining refraction, e.g. refractometers or skiascopes - A61F 9/0008: {Introducing ophthalmic products into the ocular cavity or retaining products therein (putting in contact lenses A61F9/0061; introducing or retaining media in cavities of the body in general A61M31/00)} - A61F 9/0079: {using non-laser electromagnetic radiation, e.g. non-coherent light or microwaves} - A61N 5/0601: {Apparatus for use inside the body} - A61N 5/062: {Photodynamic therapy, i.e. excitation of an agent} - A61B 3/117: for examining the anterior chamber or the anterior chamber angle, e.g. gonioscopes - A61M 2210/0612: Eyes - A61N 2005/0651: {Diodes} - A61N 2005/0658: {characterised by the wavelength of light used} - A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D) - A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C) - A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B) - A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)} ## Abstract A method of mitigating the development of myopia, includes measuring elasticity of collagen of an eye; identifying an eye for which the elasticity measured is above a preselected threshold; selectively applying a collagen cross-linking reagent proximate collagen of a sclera of a posterior pole portion of the eye for which the elasticity measured is above the preselected threshold; and irradiating at least the posterior pole portion of the eye with radiation of an appropriate wavelength to initiate covalent bonding and cross-linking of the collagen for which the elasticity measured is above the preselected threshold. ## Claims ### Claim 1 A method of mitigating the development of myopia, comprising: measuring elasticity of collagen of an eye; identifying an eye for which the elasticity measured is above a preselected threshold; selectively applying a collagen cross-linking reagent proximate collagen of a sclera of a posterior pole portion of the eye for which the elasticity measured is above the preselected threshold; and irradiating at least the posterior pole portion of the eye with radiation of an appropriate wavelength to initiate covalent bonding and cross-linking of the collagen for which the elasticity measured is above the preselected threshold. ### Claim 2 (depends on 1) The method claimed in claim 1, further comprising measuring the elasticity of the collagen of the eye utilizing an instrument selected from a group consisting of an ORA instrument and a Corvis® instrument. ### Claim 3 (depends on 1) The method as claimed in claim 1, further comprising irradiating at least the posterior pole portion of the eye by inserting an instrument exterior to the sclera and directing the radiation of the appropriate wavelength toward the sclera. ### Claim 4 (depends on 1) The method as claimed in claim 1, further comprising irradiating at least the posterior pole portion of the eye by directing radiation into the eye and then from within the eye to the sclera. ### Claim 5 (depends on 1) The method as claimed in claim 1, further comprising applying the collagen cross-linking reagent by infusing the reagent into the orbit by intra-orbital injection. ### Claim 6 (depends on 1) The method as claimed in claim 1, further comprising selecting the collagen cross-linking agent from a group consisting of riboflavin, genepin, nitroalcohols, glyceraldehyde paraformaldehyde, and glutaraldehyde. ### Claim 7 (depends on 1) The method as claimed in claim 1, further comprising applying the collagen cross-linking reagent selectively proximal the posterior pole portion of the eye and a temporal scleral portion of the eye. ### Claim 8 (depends on 1) The method as claimed in claim 1, further comprising applying the radiation of the appropriate wavelength selectively proximal to the posterior pole portion of the eye and a temporal scleral portion of the eye. ### Claim 9 (depends on 1) The method as claimed in claim 1 further comprising performing genetic evaluation to determine a risk of progressive myopia. ### Claim 10 A method of mitigating the development of progressive myopia, comprising: measuring elasticity of collagen of an eye; identifying an eye for which the elasticity measured is above a preselected threshold; selectively applying a collagen cross-linking reagent proximate collagen of a portion of a sclera extending from proximate a lamina cribrosa of the eye temporally to proximate an insertion of a lateral rectus of the eye; and irradiating the portion of a sclera extending from the lamina cribrosa temporally to an insertion of a lateral rectus of the eye with radiation of an appropriate wavelength to initiate covalent bonding and cross-linking of the collagen in the portion of a sclera extending from a lamina cribrosa temporally to an insertion of a lateral rectus of the eye. ### Claim 11 (depends on 10) The method claimed in claim 10, further comprising measuring the elasticity of the collagen of the eye utilizing an instrument selected from a group consisting of an ORA instrument and a Corvis® instrument. ### Claim 12 (depends on 10) The method as claimed in claim 10, further comprising irradiating the portion of a sclera extending from the lamina cribrosa temporally to an insertion of a lateral rectus of the eye by inserting an instrument exterior to the sclera and directing the radiation of the appropriate wavelength toward the sclera. ### Claim 13 (depends on 10) The method as claimed in claim 10, further comprising irradiating the portion of a sclera extending from the lamina cribrosa temporally to an insertion of a lateral rectus of the eye by directing radiation into the eye and then from within the eye to the sclera. ### Claim 14 (depends on 10) The method as claimed in claim 10, further comprising applying the collagen cross-linking reagent by infusing the reagent into the orbit by intra-orbital injection. ### Claim 15 (depends on 10) The method as claimed in claim 10, further comprising selecting the collagen cross-linking agent from a group consisting of riboflavin, genepin, nitroalcohols, glyceraldehyde paraformaldehyde, and glutaraldehyde. ### Claim 16 (depends on 10) The method as claimed in claim 10, further comprising applying the collagen cross-linking reagent selectively proximal the portion of a sclera extending from the lamina cribrosa temporally to an insertion of a lateral rectus of the eye. ### Claim 17 (depends on 10) The method as claimed in claim 10, further comprising applying the radiation of the appropriate wavelength selectively proximal to the portion of a sclera extending from the lamina cribrosa temporally to an insertion of a lateral rectus of the eye. ### Claim 18 (depends on 10) The method as claimed in claim 10, further comprising prescribing base in prism for an individual identified as being at rest for development of the progressive myopia. ### Claim 19 (depends on 18) The method as claimed in claim 18, further comprising prescribing the base in prism in a range of between 10 and 12 prism diopters. ### Claim 20 (depends on 10) The method as claimed in claim 10 further comprising performing genetic evaluation to determine a risk of progressive myopia.